843 related articles for article (PubMed ID: 35671984)
21. Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy : A Cohort Study.
McCreary EK; Lemon L; Megli C; Oakes A; Seymour CW;
Ann Intern Med; 2022 Dec; 175(12):1707-1715. PubMed ID: 36375150
[TBL] [Abstract][Full Text] [Related]
22. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
23. COVID-19 vaccination in pregnancy: early experience from a single institution.
Trostle ME; Limaye MA; Avtushka V; Lighter JL; Penfield CA; Roman AS
Am J Obstet Gynecol MFM; 2021 Nov; 3(6):100464. PubMed ID: 34411758
[TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 infection in pregnancy during the first wave of COVID-19 in the Netherlands: a prospective nationwide population-based cohort study (NethOSS).
Overtoom EM; Rosman AN; Zwart JJ; Vogelvang TE; Schaap TP; van den Akker T; Bloemenkamp K
BJOG; 2022 Jan; 129(1):91-100. PubMed ID: 34494694
[TBL] [Abstract][Full Text] [Related]
25. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
[TBL] [Abstract][Full Text] [Related]
26. Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
Portal-Celhay C; Forleo-Neto E; Eagan W; Musser BJ; Davis JD; Turner KC; Norton T; Hooper AT; Hamilton JD; Pan C; Mahmood A; Baum A; Kyratsous CA; Kim Y; Parrino J; Kampman W; Roque-Guerrero L; Stoici R; Fatakia A; Soo Y; Geba GP; Kowal B; DiCioccio AT; Stahl N; Lipsich L; Braunstein N; Herman GA; Yancopoulos GD; Weinreich DM;
JAMA Netw Open; 2022 Aug; 5(8):e2225411. PubMed ID: 35969402
[TBL] [Abstract][Full Text] [Related]
27. Pregnant women with severe or critical coronavirus disease 2019 have increased composite morbidity compared with nonpregnant matched controls.
DeBolt CA; Bianco A; Limaye MA; Silverstein J; Penfield CA; Roman AS; Rosenberg HM; Ferrara L; Lambert C; Khoury R; Bernstein PS; Burd J; Berghella V; Kaplowitz E; Overbey JR; Stone J
Am J Obstet Gynecol; 2021 May; 224(5):510.e1-510.e12. PubMed ID: 33221292
[TBL] [Abstract][Full Text] [Related]
28. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
29. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
30. Subcutaneous REGEN-COV antibody administration in a community pharmacy.
Dougherty TS; McBride J; Barnett CL; Gabriel WM
J Am Pharm Assoc (2003); 2023; 63(3):961-966. PubMed ID: 36710148
[TBL] [Abstract][Full Text] [Related]
31. The clinical effectiveness of REGEN-COV in SARS-CoV-2 infection with Omicron versus Delta variants.
Gershengorn HB; Patel S; Ferreira T; Das S; Parekh DJ; Shukla B
PLoS One; 2022; 17(12):e0278770. PubMed ID: 36459537
[TBL] [Abstract][Full Text] [Related]
32. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
33. Maternal and perinatal outcomes of SARS-CoV-2 infection in unvaccinated pregnancies during Delta and Omicron waves.
Birol Ilter P; Prasad S; Mutlu MA; Tekin AB; O'Brien P; von Dadelszen P; Magee LA; Tekin S; Tug N; Kalafat E; Khalil A
Ultrasound Obstet Gynecol; 2022 Jul; 60(1):96-102. PubMed ID: 35441407
[TBL] [Abstract][Full Text] [Related]
34. Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19.
Parums DV
Med Sci Monit; 2021 Aug; 27():e934393. PubMed ID: 34393218
[TBL] [Abstract][Full Text] [Related]
35. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
36. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Coronavirus Disease 2019 (COVID-19).
Mayer C; VanHise K; Caskey R; Naqvi M; Burwick RM
Obstet Gynecol; 2021 Dec; 138(6):937-939. PubMed ID: 34583385
[TBL] [Abstract][Full Text] [Related]
38. Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study.
Villar J; Ariff S; Gunier RB; Thiruvengadam R; Rauch S; Kholin A; Roggero P; Prefumo F; do Vale MS; Cardona-Perez JA; Maiz N; Cetin I; Savasi V; Deruelle P; Easter SR; Sichitiu J; Soto Conti CP; Ernawati E; Mhatre M; Teji JS; Liu B; Capelli C; Oberto M; Salazar L; Gravett MG; Cavoretto PI; Nachinab VB; Galadanci H; Oros D; Ayede AI; Sentilhes L; Bako B; Savorani M; Cena H; García-May PK; Etuk S; Casale R; Abd-Elsalam S; Ikenoue S; Aminu MB; Vecciarelli C; Duro EA; Usman MA; John-Akinola Y; Nieto R; Ferrazi E; Bhutta ZA; Langer A; Kennedy SH; Papageorghiou AT
JAMA Pediatr; 2021 Aug; 175(8):817-826. PubMed ID: 33885740
[TBL] [Abstract][Full Text] [Related]
39. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
[TBL] [Abstract][Full Text] [Related]
40. Casirivimab/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital.
Keshishian E; Kuge E; Memmott J; Hasenbalg P; Belford N; Matlock A; Schritter S; Agbayani G; Dietrich T; Santarelli A; Ashurst J
J Osteopath Med; 2022 Dec; 122(12):635-640. PubMed ID: 36123325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
